Dalfampridine in Parkinson's disease related gait dysfunction: A randomized double blind trial

Corneliu C Luca, Gloria Nadayil, Chuanhui Dong, Fatta B. Nahab, Edelle Field-Fote, Carlos Singer

Research output: Contribution to journalArticle

Abstract

Background Disease-related gait dysfunction causes extensive disability for persons with Parkinson's disease (PD), with no effective therapies currently available. The potassium channel blocker dalfampridine has been used in multiple neurological conditions and improves walking in persons with multiple sclerosis. Objectives We aimed to evaluate the effect of dalfampridine extended release (D-ER) 10 mg tablets twice daily on different domains of walking in participants with PD. Methods Twenty-two participants with PD and gait dysfunction were randomized to receive D-ER 10 mg twice daily or placebo for 4 weeks in a crossover design with a 2-week washout period. The primary outcomes were change in the gait velocity and stride length. Results At 4 weeks, gait velocity was not significantly different between D-ER (0.89 m/s ± 0.33) and placebo (0.93 m/s ± 0.27) conditions. The stride length was also similar between conditions: 0.96 m ± 0.38 for D-ER versus 1.06 m ± 0.33 for placebo. D-ER was generally well tolerated with the most frequent side effects being dizziness, nausea and balance problems. Conclusions D-ER is well tolerated in PD patients, however it did not show significant benefit for gait impairment.

Original languageEnglish (US)
Pages (from-to)7-11
Number of pages5
JournalJournal of the Neurological Sciences
Volume379
DOIs
StatePublished - Aug 15 2017

Fingerprint

Gait
Parkinson Disease
Placebos
Walking
Potassium Channel Blockers
Dizziness
Disabled Persons
Cross-Over Studies
Nausea
Tablets
Multiple Sclerosis
Therapeutics

Keywords

  • Dalfampridine
  • Freezing of gait
  • Gait dysfunction
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Dalfampridine in Parkinson's disease related gait dysfunction : A randomized double blind trial. / Luca, Corneliu C; Nadayil, Gloria; Dong, Chuanhui; Nahab, Fatta B.; Field-Fote, Edelle; Singer, Carlos.

In: Journal of the Neurological Sciences, Vol. 379, 15.08.2017, p. 7-11.

Research output: Contribution to journalArticle

@article{041865268a784dd0891a6db4b59043d8,
title = "Dalfampridine in Parkinson's disease related gait dysfunction: A randomized double blind trial",
abstract = "Background Disease-related gait dysfunction causes extensive disability for persons with Parkinson's disease (PD), with no effective therapies currently available. The potassium channel blocker dalfampridine has been used in multiple neurological conditions and improves walking in persons with multiple sclerosis. Objectives We aimed to evaluate the effect of dalfampridine extended release (D-ER) 10 mg tablets twice daily on different domains of walking in participants with PD. Methods Twenty-two participants with PD and gait dysfunction were randomized to receive D-ER 10 mg twice daily or placebo for 4 weeks in a crossover design with a 2-week washout period. The primary outcomes were change in the gait velocity and stride length. Results At 4 weeks, gait velocity was not significantly different between D-ER (0.89 m/s ± 0.33) and placebo (0.93 m/s ± 0.27) conditions. The stride length was also similar between conditions: 0.96 m ± 0.38 for D-ER versus 1.06 m ± 0.33 for placebo. D-ER was generally well tolerated with the most frequent side effects being dizziness, nausea and balance problems. Conclusions D-ER is well tolerated in PD patients, however it did not show significant benefit for gait impairment.",
keywords = "Dalfampridine, Freezing of gait, Gait dysfunction, Parkinson's disease",
author = "Luca, {Corneliu C} and Gloria Nadayil and Chuanhui Dong and Nahab, {Fatta B.} and Edelle Field-Fote and Carlos Singer",
year = "2017",
month = "8",
day = "15",
doi = "10.1016/j.jns.2017.05.011",
language = "English (US)",
volume = "379",
pages = "7--11",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Dalfampridine in Parkinson's disease related gait dysfunction

T2 - A randomized double blind trial

AU - Luca, Corneliu C

AU - Nadayil, Gloria

AU - Dong, Chuanhui

AU - Nahab, Fatta B.

AU - Field-Fote, Edelle

AU - Singer, Carlos

PY - 2017/8/15

Y1 - 2017/8/15

N2 - Background Disease-related gait dysfunction causes extensive disability for persons with Parkinson's disease (PD), with no effective therapies currently available. The potassium channel blocker dalfampridine has been used in multiple neurological conditions and improves walking in persons with multiple sclerosis. Objectives We aimed to evaluate the effect of dalfampridine extended release (D-ER) 10 mg tablets twice daily on different domains of walking in participants with PD. Methods Twenty-two participants with PD and gait dysfunction were randomized to receive D-ER 10 mg twice daily or placebo for 4 weeks in a crossover design with a 2-week washout period. The primary outcomes were change in the gait velocity and stride length. Results At 4 weeks, gait velocity was not significantly different between D-ER (0.89 m/s ± 0.33) and placebo (0.93 m/s ± 0.27) conditions. The stride length was also similar between conditions: 0.96 m ± 0.38 for D-ER versus 1.06 m ± 0.33 for placebo. D-ER was generally well tolerated with the most frequent side effects being dizziness, nausea and balance problems. Conclusions D-ER is well tolerated in PD patients, however it did not show significant benefit for gait impairment.

AB - Background Disease-related gait dysfunction causes extensive disability for persons with Parkinson's disease (PD), with no effective therapies currently available. The potassium channel blocker dalfampridine has been used in multiple neurological conditions and improves walking in persons with multiple sclerosis. Objectives We aimed to evaluate the effect of dalfampridine extended release (D-ER) 10 mg tablets twice daily on different domains of walking in participants with PD. Methods Twenty-two participants with PD and gait dysfunction were randomized to receive D-ER 10 mg twice daily or placebo for 4 weeks in a crossover design with a 2-week washout period. The primary outcomes were change in the gait velocity and stride length. Results At 4 weeks, gait velocity was not significantly different between D-ER (0.89 m/s ± 0.33) and placebo (0.93 m/s ± 0.27) conditions. The stride length was also similar between conditions: 0.96 m ± 0.38 for D-ER versus 1.06 m ± 0.33 for placebo. D-ER was generally well tolerated with the most frequent side effects being dizziness, nausea and balance problems. Conclusions D-ER is well tolerated in PD patients, however it did not show significant benefit for gait impairment.

KW - Dalfampridine

KW - Freezing of gait

KW - Gait dysfunction

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85019404751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019404751&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2017.05.011

DO - 10.1016/j.jns.2017.05.011

M3 - Article

C2 - 28716283

AN - SCOPUS:85019404751

VL - 379

SP - 7

EP - 11

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -